Cartistem

BIOLOGICAL3 trials

Sponsors

Medipost Co Ltd., Samsung Medical Center

Conditions

Cartilage InjuryDefect of Articular CartilageDegenerative OsteoarthritisOsteoarthritisOsteochondral Lesion of Talus

Early Phase 1

Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product

Samsung Medical CenterOsteochondral Lesion of Talus

Start: 2012-12-31End: 2015-12-31Updated: 2015-01-14

Phase 3

Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury

CompletedNCT01041001

Medipost Co Ltd.Cartilage Injury, Osteoarthritis

Start: 2009-02-28End: 2011-01-31Updated: 2017-04-20

Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect

CompletedNCT01626677

Medipost Co Ltd.Defect of Articular Cartilage, Degenerative Osteoarthritis

Start: 2012-06-30End: 2015-05-31Updated: 2017-04-20

Related Papers

Allogeneic Umbilical Cord Blood–Derived Mesenchymal Stem Cell Implantation Versus Microfracture for Large, Full-Thickness Cartilage Defects in Older Patients: A Multicenter Randomized Clinical Trial and Extended 5-Year Clinical Follow-up

Orthopaedic Journal of Sports Medicine2021-01-0190 citations

Clinical Trial of Osteochondral Lesion of Talus Treated with Human Mesenchymal Stem Cell

Foot & Ankle Orthopaedics2016-08-01